Quantum biochemistry description of PI3Kα enzyme bound to selective inhibitors

被引:0
|
作者
de Sousa, Francisca Joseli Freitas [1 ]
Azevedo, Francisca Fernanda Nunes [1 ]
de Oliveira, Francisco Lucas Santos [2 ]
Carletti, Jaqueline Vieira [3 ]
Freire, Valder Nogueira [4 ]
Zanatta, Geancarlo [1 ,2 ]
机构
[1] Univ Fed Ceara, Dept Biochem & Mol Biol, Fortaleza, Brazil
[2] Univ Fed Rio Grande do Sul, Dept Biophys, Porto Alegre, Brazil
[3] Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, Brazil
[4] Univ Fed Ceara, Dept Phys, Fortaleza, Brazil
关键词
Alpelisib; GDC-0326; PI3K alpha-inhibitors; phosphoinositide-3-kinase; molecular fragmentation with conjugated caps; quantum calculation; POPULATION ANALYSIS; INFORMATION-THEORY; ISOFORM; IDENTIFICATION; MECHANICS; BINDING; DESIGN; NVP-BYL719; MOLECULES; DISCOVERY;
D O I
10.1080/07391102.2023.2251063
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PI3K class I is composed of four PI3K isoforms that serve as regulatory enzymes governing cellular metabolism, proliferation, and survival. The hyperactivation of PI3K alpha is observed in various types of cancer and is linked to poor prognosis. Unfortunately, the development inhibitors selectively targeting one of the isoforms remains challenging, with only few agents in clinical use. The main difficulty arises from the high conservation among residues at the ATP-binding pocket across isoforms, which also serves as target pocket for inhibitors. In this work, molecular dynamics and quantum calculations were performed to investigate the molecular features guiding the binding of selective inhibitors, alpelisib and GDC-0326, into the ATP-binding pocket of PI3K alpha. While molecular dynamics allowed crystallographic coordinates to relax, the interaction eergy between each amino acid residues and inhibitors was obtained by combining the Molecular Fractionation with Conjugated Caps scheme with Density Functional Theory calculations. In addition, the atomic charge of ligands in the bound and unbound (free) was calculated. Results indicated that the most relevant residues for the binding of alpelisib are Ile932, Glu859, Val851, Val850, Tyr836, Met922, Ile800, and Ile848, while the most important residues for the binding of GDC-0326 are Ile848, Ile800, Ile932, Gln859, Glu849, and Met922. In addition, residues Trp780, Ile800, Tyr836, Ile848, Gln859 Val850, Val851, Ile932 and Met922 are common hotspots for both inhibitors. Overall, the results from this work contribute to improving the understanding of the molecular mechanisms controlling selectivity and highlight important interactions to be considered during the rational design of new agents.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Horizons broaden for PI3Kδ inhibitors
    Kingwell, Katie
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (08) : 573 - 573
  • [42] PI3Kα Inhibitors That Inhibit Metastasis
    Schmidt-Kittler, Oleg
    Zhu, Jiuxiang
    Yang, Jian
    Liu, Guosheng
    Hendricks, William
    Lengauer, Christoph
    Gabelli, Sandra B.
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Huso, David L.
    Zhou, Shibin
    [J]. ONCOTARGET, 2010, 1 (05) : 339 - 348
  • [43] Cardiovascular toxicity of PI3Kα inhibitors
    Sadasivan, Chandu
    Zhabyeyev, Pavel
    Labib, Dina
    White, James A.
    Paterson, D. Ian
    Oudit, Gavin Y.
    [J]. CLINICAL SCIENCE, 2020, 134 (19): : 2595 - 2622
  • [44] Clinical development of inhibitors of the PI3K
    Saura Manich, C.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [45] The development of inhibitors of PI3K and Akt
    Dennis, PA
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [46] PI3K inhibitors in haematological malignancies
    Matasar, Matthew J.
    Hiemeyer, Florian
    Childs, Barrett H.
    Zinzani, Pier Luigi
    [J]. LANCET ONCOLOGY, 2022, 23 (08): : E365 - E365
  • [47] LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family
    Chiosis, G
    Rosen, N
    Sepp-Lorenzino, L
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (07) : 909 - 913
  • [48] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [49] Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
    Han, Fangbin
    Lin, Songwen
    Liu, Peng
    Liu, Xiujie
    Tao, Jing
    Deng, Xiaobing
    Yi, Chongqin
    Xu, Heng
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (04): : 434 - 438
  • [50] PI3K delta: Discovery of potent and selective inhibitors for treating hematopoietic malignancies
    Mattheakis, L.
    Kearney, P.
    Jaeger, C.
    Plonowski, A.
    Zhang, J.
    Yu, P.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 72 - 72